Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders.
Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com.
Further information: www.asceneuron.com
Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com.
Further information: www.asceneuron.com
Location: Switzerland, Vaud, Lausanne
Employees: 1-10
Total raised: $130.85M
Founded date: 2012
Investors 4
| Date | Name | Website |
| - | M Ventures | m-ventures... |
| - | Sofinnova ... | sofinnovap... |
| - | Kurma Part... | kurmapartn... |
| - | SR One | srone.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.07.2024 | Series C | $100M | EQT |
| 29.09.2015 | Series A | $30.85M | - |
Mentions in press and media 23
| Date | Title | Description |
| 18.07.2024 | Asceneuron's $100M Series C Funding Boosts Alzheimer's Disease Research | Asceneuron, a Lausanne-based clinical-stage biotech company, has recently announced the successful completion of a $100 million Series C financing round. This significant funding boost, led by Novo Holdings and supported by EQT Life Science... |
| 16.07.2024 | Asceneuron Raises $100M in Series C Financing | Asceneuron, a Lausanne, Switzerland-based clinical stage biotech company developing small molecules targeting tau protein aggregation, raised $100M in Series C funding. The round was led by Novo Holdings with new investment from EQT Life Sc... |
| 16.07.2024 | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round Tue, Jul 16, 2024 09:15 CET Report this content EQT Life Sciences has invested in Asceneuron’s oversubscr... |
| 16.07.2024 | Asceneuron closes $100 million series C financing round | Asceneuron SA, a Lausanne-based clinical-stage biotech company developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease, announces its $100 million oversubscribed Series C financing round. The... |
| 16.10.2023 | Industry leaders to take startups to new heights | |
| 23.02.2023 | Asceneuron PSP Candidate Treatment rights sold to Ferrer | |
| 05.05.2022 | Asceneuron obtains grant to advance treatment for Parkinson’s Disease | |
| 20.07.2021 | Startups welcome legendary board members aboard | DiNAQor – three prominent cardiovascular industry and Academic Experts Louis G. Lange, Steven Zelenkofske, and Silke Rickert-Sperling, some of the most renowned cardiovascular industry and academic experts are joining the board of directors... |
| 12.03.2021 | Asceneuron awarded USD 2.2 million to advance into phase 1 clinical trials | |
| 12.03.2021 | Asceneuron awarded USD 2.2 million to advance into phase 1 clinical trials | Asceneuron is a clinical-stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatment... |
Show more